-

01:04:38 PM

ADMA Stock News

ADMA - Adma Biologics Inc

08/09/23 4:05 PM

Nasdaq : ADMA

earnings

ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update

2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA (1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss (2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million Adjusted

RHEA-AI

neutral

08/02/23 7:00 AM

Nasdaq : ADMA

conferencesearnings

ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and

RHEA-AI

neutral

07/19/23 7:00 AM

Nasdaq : ADMA

fda approval

ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

ADMA Biologics,

RHEA-AI

neutral

05/10/23 4:05 PM

Nasdaq : ADMA

earnings

ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update

1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1 ) , Totaling $2.5 Million, Earlier Than Forecasted FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased from

RHEA-AI

neutral

05/03/23 7:00 AM

Nasdaq : ADMA

conferencesearnings

ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing

RHEA-AI

neutral

05/02/23 7:00 AM

Nasdaq : ADMA

ADMA Biologics Announces Amendment to Credit Agreement

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the

RHEA-AI

neutral

03/23/23 4:05 PM

Nasdaq : ADMA

earnings

ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million First-Time Positive EBITDA Expected No Later than Second Half of 2023 Conference Call Scheduled for Today at 4:30 p.m.

RHEA-AI

positive

03/16/23 7:00 AM

Nasdaq : ADMA

conferencesearnings

ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and

RHEA-AI

neutral

02/08/23 7:00 AM

Nasdaq : ADMA

fda approval

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

ADMA Biologics,

RHEA-AI

very positive

01/17/23 7:00 AM

Nasdaq : ADMA

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance

Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021 Full Year 2023 Total Revenues are Expected to be $210

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 Next

ADMA Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websiteadmabiologics.com
Security nameAdma Biologics Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About Adma Biologics Inc

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.